Immutep Celebrates Key Milestone in Oncology Development
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has recently achieved an important milestone in its journey towards revolutionizing cancer treatment. The company announced that it has successfully completed the necessary requirements for Project Optimus, a vital step in the development of its promising immunotherapy drug, Eftilagimod Alfa (efti). This milestone meets the U.S. Food and Drug Administration (FDA) standards for dose determination in clinical studies, confirming the 30mg dosage as optimal for its oncology pipeline.
Positive Feedback from the FDA
The FDA's positive feedback marks a significant progression in Immutep’s clinical development initiatives. Christian Mueller, Chief Development Officer at Immutep, expressed gratitude for the collaborative discussions held with the FDA, highlighting how the agreement on the optimal biologic dose for efti is a crucial building block for future Biological License Applications (BLA). This strategic alignment supports the company’s ongoing efforts to bring innovative cancer therapies to patients in need worldwide.
The Impact on Efti’s Clinical Programs
The agreement on efti's optimal dosage holds strategic relevance as Immutep continues to develop this first-in-class immunotherapy. The Company is actively preparing for its global TACTI-004 Phase III trial, known as KEYNOTE-F91, which aims to evaluate the efficacy of efti combined with MSD's (Merck & Co., Inc.) anti-PD-1 therapy, KEYTRUDA, and chemotherapy for treating advanced or metastatic non-small cell lung cancer (NSCLC) in patients.
Further Developments in Cancer Treatments
The TACTI-004 trial is currently in progress, with sites across the United States being opened to facilitate patient recruitment. Efti is also undergoing evaluation across various solid tumors, including head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its versatile safety profile allows it to be used in combination with existing therapies like anti-PD-L1 immunotherapy, thereby increasing the hope for positive outcomes in treating diverse cancer types.
About Eftilagimod Alfa (Efti)
Efti stands out as a novel immunotherapy that actively stimulates antigen-presenting cells (APCs) through the MHC Class II pathway. This process enhances the immune system's capability to combat cancer by activating cytotoxic T cells and generating crucial co-stimulatory signals that further strengthen the immune response. The FDA has granted Fast Track designation for use in both first-line HNSCC and NSCLC treatment, underscoring the drug's potential clinical significance.
Immutep's Mission and Vision
Founded on a pioneering quest to enhance cancer therapies, Immutep is dedicated to the development of innovative immunotherapies. With a focus on Lymphocyte Activation Gene-3 (LAG-3), the Company’s research portfolio strategically leverages LAG-3’s mechanism to stimulate or inhibit immune responses. Immutep’s commitment to providing effective treatment solutions aligns with its goal to maximize shareholder value while transforming the treatment landscape for cancer patients.
Key Contacts for Investors and Media
The Company remains open for inquiries from both Australian and U.S. investors, with dedicated contacts available for media and investor relations. For Australian media inquiries, Eleanor Pearson from Sodali & Co. can be reached at +61 2 9066 4071 or via email at eleanor.pearson@sodali.com. U.S. media inquiries can be directed to Chris Basta, VP of Investor Relations, at +1 (631) 318 4000 or chris.basta@immutep.com.
Frequently Asked Questions
What is Immutep's recent milestone?
Immutep has successfully completed the FDA’s Project Optimus requirements, confirming the optimal dosage for its drug, Eftilagimod Alfa.
What is Eftilagimod Alfa?
Eftilagimod Alfa (efti) is an innovative immunotherapy that works by activating the body's immune response to target cancer cells.
How is Efti being tested?
Efti is undergoing evaluation in the TACTI-004 (KEYNOTE-F91) Phase III trial, which assesses its effectiveness in combination therapy for lung cancer.
What are the strategic implications of the FDA agreement?
The agreement sets the foundation for future BLA filings and enhances confidence in efti’s clinical development.
Where can I find more information about Immutep?
More information can be found on Immutep's official website at www.immutep.com.
